Levodopa-related motor complications - Phenomenology

Movement Disorders

Volumn 23, Issue SUPPL. 3, 2008, Pages

  Fox, Susan H ^a   Lang, Anthony E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Levopoda; Motor fluctuations; Non motor; Parkinson's disease

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PARKIN;

AKATHISIA; AKINESIA; ANXIETY; APATHY; ARTICLE; AUTONOMIC DYSFUNCTION; BEHAVIOR DISORDER; BLADDER DISEASE; BLOATING; BRADYKINESIA; CHOREA; CLINICAL ASSESSMENT; COLON DISEASE; COMPULSION; CONSTIPATION; DAYTIME SOMNOLENCE; DELUSION; DEPRESSION; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSKINESIA; DYSPHAGIA; DYSPNEA; DYSTONIA; EUPHORIA; FATIGUE; FLUSHING; FOOD; FOOD DRUG INTERACTION; GENE MUTATION; HUMAN; HYPERSALIVATION; HYPERSEXUALITY; HYPERTHERMIA; LONG TERM CARE; MENTAL DISEASE; MOOD DISORDER; MORNING DOSAGE; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; MUSCLE STIFFNESS; MYALGIA; MYOCLONUS; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; PALLOR; PANIC; PARANOIA; PARESTHESIA; PARKINSON DISEASE; PARKINSONISM; PATHOLOGICAL GAMBLING; PERIPHERAL EDEMA; PHENOMENOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN INTAKE; PSYCHOMOTOR DISORDER; RESTLESS LEGS SYNDROME; RESTLESSNESS; SIDE EFFECT; SINGLE DRUG DOSE; SWEATING; SYMPTOM; TACHYCARDIA; TREMOR; URINARY FREQUENCY; VISUAL HALLUCINATION; XEROSTOMIA;

ANTIPARKINSON AGENTS; COGNITION DISORDERS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DYSKINESIAS; FATIGUE; HUMANS; LEVODOPA; MOOD DISORDERS; MOTOR ACTIVITY; PARKINSON DISEASE; TREATMENT FAILURE;

EID: 53149141027     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22021     Document Type: Article

References (63)

1. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
2. Quinn NP. Classification of fluctuations in patients with Parkinson's disease. Neurology 1998;51 (Suppl 2)25-29.
3. Muenter MD, Tyce GM. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971;46:231-239.
4. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-573.
5. Obeso JA, Rodriguez-Oroz MC, Chana P, Lera G, Rodriguez M, Olanow CW. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000;55 (Suppl 4)S13-S20.
6. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
7. Hauser RA, Koller WC, Hubble JP, Malapira T, Busenbark K, Olanow CW. Time course of loss of clinical benefit following withdrawal of levodopa/ carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 2000;15:485-489.
8. Hauser RA, Holford NH. Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. Mov Disord 2002;17: 961-968.
9. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
10. Quattrone A, Zappia M, Aguglia U, et al. The subacute levodopa test for evaluating long-duration response in Parkinson's disease. Ann Neurol 1995;38:389-395.
11. Nutt JG, Carter JH, Lea ES, Sexton GJ. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 2002;51:686-693.
12. Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 1996;60:634-637.
13. Shoulson I, Glaubiger GA, Chase TN. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in Parkinsonian patients. Neurology 1975;25:1144-1148.
14. Fahn S. Fluctuations of disability in Parkinson's disease: pathophysiological aspects. In: Marsden CD, Fahn S, Editors. Movement disorders. London: Butterworth Scientific; 1982. p 123-145.
15. Fahn S. "On-off" phenomenon with levodopa therapy in parkinsonism: clinical and pharmacological correlations and the effects of intramuscular pyridoxine. Neurology 1974;24:431-444.
16. Melamed E, Bitton V. Delayed onset of responses to individual doses of L-dopa in Parkinsonian fluctuators: an additional side effect of long-term L-dopa therapy. Neurology 1984;34 (Suppl 2): 270.
17. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35-49.
18. Baruzzi A, Contin M, Riva R, et al. Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients. Clin Neuropharmacol 1987;10:527-537.
19. Pierantozzi M, Pietroiusti A, Brusa L, et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology 2006;66:1824-1829.
20. Merello M, Lees AJ. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55: 1024-1026.
21. Nutt JG, Gancher ST, Woodward WR. Does an inhibitory action of levodopa contribute to motor fluctuations? Neurology 1988; 38:1553-1557.
22. Giladi N, McMahon D, Przedborski S, et al. Motor blocks in Parkinson's disease. Neurology 1992;42:333-339.
23. Fahn S. The freezing phenomenon in parkinsonism. Adv Neurol 1995;67:53-63.
24. Ambani LM, Van Woert MH. Start hesitation-a side effect of long-term levodopa therapy. N Engl J Med 1973;288:1113-1115.
25. Barbeau A. Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch Neurol 1976;33:333-338.
26. Nutt JG. Levodopa-induced dyskinesia: review, observation and speculations. Neurology 1990,40:340-345.
27. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-124.
28. Jankovic J, Nour F. Respiratory dyskinesia in Parkinson's disease. Neurology 1986;36:303-304.
29. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
30. Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol 1988;23:73-78.
31. Bravi D, Mouradian MM, Roberts JW, Davis TL, Chase TN. End-of-dose dystonia in Parkinson's disease. Neurology 1993; 43:2130-2131.
32. Melamed E. Early morning dystonia: a late side effect of long-term levodopa therapy in Parkinson's disease. Arch Neurol 1979;36:308-310.
33. Cubo E, Gracies JM, Benabou R, et al. Early morning off-medication dyskinesias, dystonia, and choreic subtypes. Arch Neurol 2001;58:1379-1382.
34. Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia (I-D-I and D-I-D) in response to L-dopa therapy in Parkinson's disease. Mayo Clin Proc 1977;52:163-174.
35. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease-clinical aspects. In: Marsden CD, Fahn S, Editors. Movement disorders. London: Butterworth Scientific; 1982. p 96-122.
36. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-719.
37. Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-414.
38. Pechevis M, Clarke CE, Vieregge P, et al. Trial study group. effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol. 2005;12:956-963.
39. Duvoisin RC. Variations in the "on-off" phenomena. Adv Neurol 1974;5:339-340.
40. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;1:292-296.
41. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms Part II Ann Neurol 1988;24:372-378.
42. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-681.
43. Struck LK, Rodnitzky RL, Dobson JK. Circadian fluctuations of contrast sensitivity in Parkinson's disease. Neurology 1990;40: 467-470.
44. Bateman DE, Levett K, Marsden CD. Sleep benefit in Parkinson's disease. J Neurol Neurosurg Psychiarty 1999;67:384-385.
45. Khan NL, Graham E, Critchley P, et al. Parkin disease: a phenotypic study of a large case series. Brain 2003;126:1279-1292.
46. Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993;43:1459-1464.
47. Lang AE, Lozano AM. Parkinson's disease. First of two parts. N Engl J Med 1998;39:1044-1053.
48. Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 2001;16:507-510.
49. Raudino F. Non motor off in Parkinson's disease. Acta Neurol Scand 2001;104:312-315.
50. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002;59: 408-413.
51. Quinn NP, Koller WC, Lang AE, Marsden CD. Painful Parkinson's disease. Lancet 1996;14:1366-1369.
52. Nissenbaum H, Quinn NP, Brown RG, Toone B, Gotham AM, Marsden CD. Mood swings associated with the 'on-off' phenomenon in Parkinson's disease. Psychol Med 1987;17:899-904.
53. Giovannoni G, O'sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-428.
54. Lawrence AD, Evans AH, Lees AJ. Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry? Lancet Neurol 2003;2:595-604.
55. Friedman JH. Punding on levodopa. Biol Psychiatry 1994;36: 350-351.
56. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397-405.
57. Defer GL, Widner H, Marie RM, Remy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999;4:572-584.
58. Widner H, Defer GL. Dyskinesias assessment: from CAPIT to CAPSIT. Core assessment program for intracerebral transplantations core assessment program for surgical interventional therapies. Mov Disord 1999;14 (Suppl 1)60-66.
59. Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000;23:75-81.
60. Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006;63:205-209.
61. Nyholm D, Kowalski J, Aquilonius SM. Wireless real-time electronic data capture for self-assessment of motor function and quality of life in Parkinson's disease. Mov Disord 2004;19:446-451.
62. Manson AJ, Brown P, O'sullivan JD, Asselman P, Buckwell D, Lees AJ. An ambulatory dyskinesia monitor. J Neurol Neurosurg Psychiatry 2000;68:196-201.
63. Van Someren EJ, Pticek MD, Speelman JD, Schuurman PR, Esselink R, Swaab DF. New actigraph for long-term tremor recording. Mov Disord 2006;21:1136-1143.